JY
NBSE

Jeff Yass’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Jeff Yass’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-963
Closed -$3.56K – 13458
2023
Q1 		$3.56K Sell
963
-932
-49% -$4.3K ﹤0.01% 12333
2022
Q4 		$7.21K Buy
+1,895
New +$9.72K ﹤0.01% 11988
2022
Q2 		– Sell
-917
Closed -$34K – 14234
2022
Q1 		$34K Sell
917
-760
-45% -$26.3K ﹤0.01% 12466
2021
Q4 		$94K Sell
1,677
-1,510
-47% -$101K ﹤0.01% 12190
2021
Q3 		$230K Buy
3,187
+1,190
+60% +$91.1K ﹤0.01% 11183
2021
Q2 		$191K Sell
1,997
-1,339
-40% -$148K ﹤0.01% 11647
2021
Q1 		$493K Buy
3,336
+1,347
+68% +$244K ﹤0.01% 9505
2020
Q4 		$278K Buy
+1,989
New +$322K ﹤0.01% 9415
2018
Q3 		– Sell
-419
Closed -$33K – 10455
2018
Q2 		$33K Buy
419
+393
+1,512% +$34.3K ﹤0.01% 9354
2018
Q1 		$2K Sell
26
-37
-59% -$5.5K ﹤0.01% 9207
2017
Q4 		$47K Buy
+63
New +$24.3K ﹤0.01% 8923
2017
Q1 		– Sell
-147
Closed -$88K – 10205
2016
Q4 		$88K Sell
147
-55
-27% -$58.1K ﹤0.01% 9133
2016
Q3 		$228K Buy
202
+7
+4% +$7.55K ﹤0.01% 7378
2016
Q2 		$213K Sell
195
-311
-61% -$390K ﹤0.01% 7513
2016
Q1 		$650K Buy
506
+253
+100% +$360K ﹤0.01% 5926
2015
Q4 		$622K Sell
253
-293
-54% -$450K ﹤0.01% 6353
2015
Q3 		$603K Buy
546
+364
+200% +$422K ﹤0.01% 6752
2015
Q2 		$182K Buy
182
+19
+12% +$20.5K ﹤0.01% 9360
2015
Q1 		$166K Buy
163
+54
+50% +$178K ﹤0.01% 8761
2014
Q4 		$364K Buy
+109
New +$334K ﹤0.01% 7810
2014
Q3 		– Sell
-31
Closed -$103K – 10051
2014
Q2 		$117K Sell
31
-108
-78% -$407K ﹤0.01% 9370
2014
Q1 		$759K Buy
+139
New +$732K ﹤0.01% 6016
2013
Q4 		– Sell
-27
Closed -$87K – 9443
2013
Q3 		$87K Buy
+27
New +$73.6K ﹤0.01% 8122

Other funds holding NBSE

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jeff Yass's NBSE Position: Q2 2023 in Review

Jeff Yass sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 963 shares — an estimated $3.56K sold.

Jeff Yass first reported a position in NBSE in Q3 2013 and held it in 23 quarters. The position peaked at $759K in Q1 2014. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

  • Jeff Yass reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Jeff Yass sold 963 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $3.56K.
  • Jeff Yass first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2013 and held it in 23 quarters.
  • Jeff Yass's NeuBase Therapeutics, Inc. Common Stock position peaked at $759K in Q1 2014.
  • 27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Susquehanna International Group's 13F filing for Q2 2023, filed 11 Aug 2023.